Solabegron is an investigational drug.
There have been 8 clinical trials for Solabegron.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 9th 2018.
The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].